Skip to main content
. 2007 Jun;61(s153):20–27. doi: 10.1111/j.1742-1241.2007.01361.x

Table 1.

Long-term glycaemic and lipidaemic effects of combined sulfonylurea and thiazolidinedione therapy in patients with type 2 diabetes

Study Comparator groups N Duration Glycaemic effects Lipidaemic effects
Comaschi et al., 2006 (23) Pioglitazone + sulfonylurea 6 months Significant and comparable improvementsin HbA1c at 12 months (p = 0.0001) Significant improvement across alllipid parameters
Pioglitazone + metformin
Torre et al., 2006 (79) Pioglitazone + sulfonylurea 77 6 months Not reported Significant decrease in triglyceridelevels in the pioglitazone + sulfonylurea group only Significant improvement inHDL-cholesterol levels
Pioglitazone + metformin 103
Derosa et al., 2004 (85) Glimepiride + pioglitazone 45 1 year Significant and comparable improvementsin HbA1c at 12 months (p < 0.01) Significant improvement across alllipid parameters
Glimepiride + rosiglitazone 44 Worsening of multiple lipid parameters
Ginis et al., 2006 (24) Pioglitazone + sulfonylurea 791 1 year Significant improvement in both groupsfrom baseline Pioglitazone + sulfonylurea: 6.65% Pioglitazone + metformin: 6.61% Triglycerides decreased significantlyin both groups (p < 0.0001) Overall reduction of 12.8% for bothgroups combined for total cholesterol Significant improvement in HDL- andLDL-cholesterol levels in both groups
Pioglitazone + metformin 705
PROactive Charbonnel and Scheen,2006 (22); Spanheimeret al., 2006 (78) Pioglitazone + sulfonylurea 508 3 years Significantly greater improvements overtime in HbA1c vs. placebo (p < 0.001at final visit) Significant improvement in triglycerideand HDL-cholesterol levels vs. placebo
Placebo + sulfonylurea 493
Quartet Charbonnel et al., 2005 (21) Pioglitazone + sulfonylurea 319 2 years HbA1c reduced by 1.03% Significant reduction in triglyceridesand greater increase inHDL-cholesterol (p ≤ 0.001) vs.metformin + sulfonylurea
Metformin + sulfonylurea 320 HbA1c reduced by 1.16%